LRIG1 and breast carcinoma: In ER-positive and lymph node-negative breast cancer, LRIG1 mRNA expression is correlated with prolonged relapse-free survival [12], and in a series of mixed breast cancer cohorts, low expression of LRIG1 was correlated with a shorter distant metastasis-free survival (MFS) and overall survival (OS) [16].